Page last updated: 2024-08-26

sr141716 and Cognitive Decline

sr141716 has been researched along with Cognitive Decline in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bosch, F; Busquets-Garcia, A; de la Torre, R; Dierssen, M; Falcón-Moya, R; Garzón-Montesinos, C; Gomis-González, M; Maldonado, R; Martín-García, E; Navarro-Romero, A; Ozaita, A; Pastor, A; Piazza, PV; Pizarro, N; Revest, JM; Rodríguez-Moreno, A; Vázquez-Oliver, A	1

Other Studies

1 other study(ies) available for sr141716 and Cognitive Decline

Article	Year
Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome. Neurobiology of disease, 2019, Volume: 125 Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Cognition; Cognitive Dysfunction; Disease Models, Animal; Down Syndrome; Female; Male; Mice; Mice, Transgenic; Neurogenesis; Phenotype; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant	2019

Article

Year

Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome.

Neurobiology of disease, 2019, Volume: 125

Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Cognition; Cognitive Dysfunction; Disease Models, Animal; Down Syndrome; Female; Male; Mice; Mice, Transgenic; Neurogenesis; Phenotype; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant

2019